

SUMMARY OF CONFIRMED INFECTIONS

Sanjib Bhattacharyya, PhD
Laboratory Director

April 2019

Trivikram Dasu, PhD, D(ABMLI)
Deputy Laboratory Director

Syphilis

| Test | Total | Test | Total |
|-------------------|-------|--------------------|-------|
| EIA Reactive | 37 | Darkfield Reactive | N/A |
| VDRL/RPR Reactive | 13 | TP-PA Reactive | 7 |

New Cases of Syphilis

| Stage | Number of Cases | |
|--------------------|-----------------|------------|
| | April 2019 | April 2018 |
| Primary syphilis | 0 | 2 |
| Secondary syphilis | 2 | 2 |
| Early latent | 2 | 2 |
| Late latent | 0 | 0 |
| Total | 4 | 6 |

Source: Wisconsin Division of Health

HIV

| Test | Total | Reactive | Percent (%) |
|---------------------|-------|----------|-------------|
| EIA-HIV Ag/Ab combo | 291 | 1 | 0.3 |

Chlamydia trachomatis (CT), *Neisseria gonorrhoeae* (GC), *Trichomonas vaginalis* (Trich), and *Mycoplasma genitalium* (Mgen) Nucleic Acid Amplification

| Source | CT | | | GC | | | Trich | | | Mgen | | |
|----------|--------|----------|-------------|--------|----------|-------------|--------|-----|-------------|--------|-----|-------|
| | Tested | Positive | Percent (%) | Tested | Positive | Percent (%) | Tested | Pos | Percent (%) | Tested | Pos | % Pos |
| Urine | 434 | 40 | 9.2 | 431 | 35 | 8.1 | 253 | 18 | 7.1 | 87 | 19 | 21.8 |
| Throat | 420 | 9 | 2.1 | 496 | 23 | 4.6 | | | | | | |
| Rectal | 170 | 14 | 8.2 | 170 | 9 | 5.3 | | | | | | |
| Vaginal | 67 | 3 | 4.5 | 67 | 11 | 16.4 | 67 | 12 | 17.9 | 0 | 0 | N/A |
| Urethral | 2 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 73 | 18 | 24.7 |

Gonorrhea Antimicrobial Susceptibility Testing

| Number Tested | Non-Susceptible (NS) / Decreased-Susceptible (DS) Antibiotics | | | |
|---------------|---|-------------|--------------|-------------|
| | Cefixime | Ceftriaxone | Azithromycin | Gentamicin* |
| 48 | 0 | 0 | 11 | 0 |

*No CLSI interpretation available

Clinical cultures of interest

| Source | Identification | Number |
|--------|------------------------------|--------|
| Cervix | <i>Neisseria gonorrhoeae</i> | 1 |
| Penis | <i>Neisseria gonorrhoeae</i> | 1 |
| Vagina | <i>Neisseria gonorrhoeae</i> | 1 |

Reference cultures

| Source | Identification | Number |
|--------|---|--------|
| Stool | <i>Bacillus amyloliquefaciens</i> * | 2 |
| Stool | <i>Bacillus pumilus</i> * | 1 |
| Stool | <i>Bacillus licheniformis</i> * | 1 |
| Stool | <i>Bacillus subtilis</i> * | 2 |
| Wound | <i>Corynebacterium pseudodiphtheriticum</i> * | 2 |
| Sputum | <i>Gordonia bronchialis</i> * | 1 |

*The MHD laboratory targets the 16S rRNA (bacterial) and the D2 region of the 28S rRNA (fungal) genes for sequence-based microbial identification of selective reference isolates.


Molecular Amplification

| Agent | Method | Tested | Positives | Percent (%) |
|----------------------|------------------|--------|-----------|-------------|
| Herpes simplex virus | Real time PCR | 26 | 10 | 38 |
| Measles virus | Real time RT-PCR | 2 | 0 | 0 |
| Mumps virus | Real time RT-PCR | 4 | 0 | 0 |
| Varicella zoster | Real time PCR | 1 | 0 | 0 |

Respiratory Pathogens Surveillance:

| Respiratory Pathogen Panel Test Results | | |
|---|-----------|-------------|
| Virus | Positives | Percent (%) |
| Human metapneumovirus | 2 | 11.7 |
| Entero/Rhinovirus | 6 | 35.3 |
| Parainfluenza virus type 2 | 0 | 0 |
| Parainfluenza virus type 3 | 0 | 0 |
| Bocavirus | 1 | 5.9% |

Specimens tested: n = 17 (April 2019)



Note: The MHDL provides comprehensive detection of multiple respiratory viruses and their subtypes: Influenza A, Influenza B, Respiratory Syncytial Virus (RSV), Human Metapneumovirus (hMPV), Enterovirus/ Rhinovirus (ENT/HRV), Adenovirus, Parainfluenza (HPIV 1-4), Coronavirus and Boca viruses. The bacterial targets include *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, and *Legionella pneumophila*